SynthesisScientific reports2015
The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis.
Synthesis in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Rituximab in pediatric refractory nephrotic syndrome: a systematic review and meta-analysis evaluating therapeutic efficacy and adverse event profiles.Pediatric nephrology (Berlin, Germany) · 2026Pooled it
- The efficacy of rituximab in the treatment of refractory nephrotic syndrome: a meta-analysis.International urology and nephrology · 2020Pooled it
- Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.Medicine · 2020Pooled it
- Rituximab shows no effect on remission in patients with refractory nephrotic syndrome: A MOOSE-compliant meta-analysis.Medicine · 2016Pooled it
- Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing.Scientific reports · 2018Trial
- Nephrotic Syndrome: A Review.Cureus · 2024Review
- Efficacy of rituximab therapy in children with nephrotic syndrome: a 10-year experience from an Iranian pediatric hospital.BMC pediatrics · 2022Article
- Tetrandrine may treat membranous glomerulopathy via P13K/Akt signaling pathway regulation: therapeutic mechanism validation using Heymann nephritis rat model.Bioengineered · 2021Article
- Observational
- Article
- Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome.Pediatric nephrology (Berlin, Germany) · 2019Observational
- Cost analysis on the use of rituximab and calcineurin inhibitors in children and adolescents with steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2018Article
- Traditional Chinese Medicine for Refractory Nephrotic Syndrome: Strategies and Promising Treatments.Evidence-based complementary and alternative medicine : eCAM · 2018Review
- Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis.Oncotarget · 2017Article
- Podocyte-actin dynamics in health and disease.Nature reviews. Nephrology · 2016Review
- The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective.Italian journal of pediatrics · 2016Review
- Pathogenesis of minimal change nephrotic syndrome: an immunological concept.Korean journal of pediatrics · 2016Review
- Cyclosporine in the treatment of childhood idiopathic steroid resistant nephrotic syndrome: a single centre experience in Nigeria.The Pan African medical journal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab is considered to be a promising drug for treating childhood refractory nephrotic syndrome. However, the efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome remain inconclusive. This meta-analysis aimed to investigate the efficacy and safety of rituximab treatment compared with other immunosuppressive agents in children with refractory nephrotic syndrome. Three randomized controlled trials and two comparative control studies were included in our analysis. The included studies were of moderately high quality. Compared with other immunotherapies, rituximab therapy significantly improved relapse-free survival (hazard ratio = 0.49, 95% confidence interval [CI], 0.26-0.92, P = 0.03). Rituximab also achieved a higher rate of complete remission (risk ratio,1.62; 95% CI, 0.92 to 2.84, P = 0.09) and reduced the occurrence of proteinuria (mean difference = -0.25, 95% CI = -0.29 to -0.21, P < 0.00001); however, a more targeted rituximab treatment did not significantly increase serum albumin levels and did not significantly reduce adverse events. Rituximab might be a promising treatment for childhood refractory nephrotic syndrome; however, the long-term effects and cost-effectiveness of rituximab treatment were not fully assessed, and there were limited studies that evaluated the clinical benefits of a concurrent infusion of rituximab plus a steroid compared with an infusion of rituximab only. Additional studies are required to address these issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.